Array BioPharma Inc. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
SummaryBusiness and Consumer Services
Key Findings
Business and Consumer Services
Business and Consumer Services
Reasons To Buys
MarketLine
Key Highlights
United States
Array BioPharma is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients with cancer and other diseases. The company's commercial and clinical stage drugs include: BRAFTOVI + MEKTOVI, which are BRAF and MEK inhibitors for BRAF-mutant melanoma; Encorafenib, a BRAF inhibitor for BRAF-mutant colorectal cancer (CRC); Binimetinib, a MEK inhibitor for CRC and other cancers; Selumetinib, a MEK inhibitor for cancer and Neurofibromatosis type 1; Ganovo/Danoprevir, a protease inhibitor for Hepatitis C virus; Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; and ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy.
MarketLine, a world-leading provider of commercial intelligence, has over 400 experienced analysts, consultants, and researchers with regional and sector expertise in market sizing, competitor tracking, socio and macro economics, and business drivers.
For more than 15 years MarketLine has supported the research needs of investment banks, corporations, professional services firms, and academia with a unique mix of company, industry, country, city and financial data for every major industry and marketplace.
MarketLine’ holistic business intelligence report collection includes:
Industry Intelligence
‒ Industry Profiles
‒ Market Forecasts
‒ Porter’s Five Forces Analysis
Company Intelligence
‒ Company Profiles
‒ SWOT Analysis
‒ Financial Deals
Country and City Intelligence
‒ Country and City Profiles
‒ PEST/PESTLE Analysis
‒ Socio and macro-economic indicators
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.